These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18498877)

  • 21. CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy.
    Zhao Y; Zhang T; Duan S; Davies NM; Forrest ML
    Nanomedicine; 2014 Aug; 10(6):1221-30. PubMed ID: 24637218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model.
    Chen FA; Kuriakose MA; Zhou MX; DeLacure MD; Dunn RL
    Head Neck; 2003 Jul; 25(7):554-60. PubMed ID: 12808659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer.
    Chen J; Wang L; Yao Q; Ling R; Li K; Wang H
    Breast Cancer Res; 2004; 6(4):R474-7. PubMed ID: 15217515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the physicochemical properties of drugs suitable for administration using a lymphatic drug delivery system.
    Fukumura R; Sukhbaatar A; Mishra R; Sakamoto M; Mori S; Kodama T
    Cancer Sci; 2021 May; 112(5):1735-1745. PubMed ID: 33629407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas.
    Venable RO; Worley DR; Gustafson DL; Hansen RJ; Ehrhart EJ; Cai S; Cohen MS; Forrest ML
    Am J Vet Res; 2012 Dec; 73(12):1969-76. PubMed ID: 23176425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.
    Kaminskas LM; Ascher DB; McLeod VM; Herold MJ; Le CP; Sloan EK; Porter CJ
    J Control Release; 2013 Jun; 168(2):200-8. PubMed ID: 23499718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
    Mittapalli RK; Liu X; Adkins CE; Nounou MI; Bohn KA; Terrell TB; Qhattal HS; Geldenhuys WJ; Palmieri D; Steeg PS; Smith QR; Lockman PR
    Mol Cancer Ther; 2013 Nov; 12(11):2389-99. PubMed ID: 24002934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
    Dhar S; Kolishetti N; Lippard SJ; Farokhzad OC
    Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1850-5. PubMed ID: 21233423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intralymphatic delivery of platinum-based chemotherapeutics is possible: an experimental study.
    Zor M; Yildirim I; Basal S; Yaman H; Ozturk M; Irkilata CH; Goktas S; Dayanc M
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1679-82. PubMed ID: 22638885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyaluronic acid-coated single-walled carbon nanotubes loaded with doxorubicin for the treatment of breast cancer.
    Liu D; Zhang Q; Wang J; Fan L; Zhu W; Cai D
    Pharmazie; 2019 Feb; 74(2):83-90. PubMed ID: 30782256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.
    Cai S; Thati S; Bagby TR; Diab HM; Davies NM; Cohen MS; Forrest ML
    J Control Release; 2010 Sep; 146(2):212-8. PubMed ID: 20403395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.
    Federico C; Sun J; Muz B; Alhallak K; Cosper PF; Muhammad N; Jeske A; Hinger A; Markovina S; Grigsby P; Schwarz JK; Azab AK
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1483-1494. PubMed ID: 33253820
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Huang C; Chen F; Zhang L; Yang Y; Yang X; Pan W
    Int J Nanomedicine; 2020; 15():2987-2998. PubMed ID: 32431497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo.
    Cohen SM; Mukerji R; Cai S; Damjanov I; Forrest ML; Cohen MS
    Am J Surg; 2011 Dec; 202(6):646-52; discussion 652-3. PubMed ID: 21982998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
    Lu B; Xiong SB; Yang H; Yin XD; Chao RB
    Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thermosensitive hydrogels composed of hyaluronic acid and gelatin as carriers for the intravesical administration of cisplatin.
    Chen JP; Leu YL; Fang CL; Chen CH; Fang JY
    J Pharm Sci; 2011 Feb; 100(2):655-66. PubMed ID: 20799367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil.
    Rosenthal MA; Gibbs P; Brown TJ; Wong S; Uren S; Ellis A; Li L; Heldin P; Fox RM
    Chemotherapy; 2005 May; 51(2-3):132-41. PubMed ID: 15886473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.